Monopar Therapeutics Inc. MNPR
71.42 USD +4.20 (+6.25%)
At closeNov 6, 2026, 4:00 PM EST
71.42 0.00 0.00%
After hours · Nov 6, 4:00 PM ET
67.45 Day range 72.25
50.12 52-week range 123.84
- YTD
- +9.37%
- 1 year
- -11.57%
News
globenewswire.com Monopar to Present at AASLD – The Liver Meeting® 2026: Phase 3 FoCus Baseline Data and ALXN1840 Molybdenum Safety Data WILMETTE, Ill., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments…
benzinga.com Barclays Maintains Overweight on Monopar Therapeutics, Raises Price Target to $145 Barclays analyst Etzer Darout maintains Monopar Therapeutics (NASDAQ:MNPR) with a Overweight and raises the price target from $128 to $145.
benzinga.com This Stubhub Analyst Turns Bearish; Here Are Top 5 Downgrades For Thursday Top Wall Street analysts changed outlook on top names. See analyst ratings page for all changes. STUB downgraded, MNPR neutral, BETR.
benzinga.com Barclays Maintains Overweight on Monopar Therapeutics, Raises Price Target to $128 Barclays analyst Etzer Darout maintains Monopar Therapeutics (NASDAQ:MNPR) with a Overweight and raises the price target from $125 to $128.
benzinga.com Cantor Fitzgerald Downgrades Monopar Therapeutics to Neutral, Raises Price Target to $119 Cantor Fitzgerald analyst Kristen Kluska downgrades Monopar Therapeutics (NASDAQ:MNPR) from Overweight to Neutral and raises the price target from $109 to $119.- benzinga.com BTIG Maintains Buy on Monopar Therapeutics, Raises Price Target to $133 BTIG analyst Jeet Mukherjee maintains Monopar Therapeutics (NASDAQ:MNPR) with a Buy and raises the price target from $117 to $133.
- benzinga.com Monopar Therapeutics Q2 EPS $(0.62) Misses $(0.56) Estimate Monopar Therapeutics (NASDAQ:MNPR) reported quarterly losses of $(0.62) per share which missed the analyst consensus estimate of $(0.56) by 10.71 percent. This is a 77.14 percent decrease over losses…
benzinga.com HC Wainwright & Co. Maintains Buy on Monopar Therapeutics, Raises Price Target to $125 HC Wainwright & Co. analyst Andres Y. Maldonado maintains Monopar Therapeutics (NASDAQ:MNPR) with a Buy and raises the price target from $105 to $125.- benzinga.com Monopar Therapeutics Begins Rolling Submission Of FDA New Drug Application For ALXN1840 Albumin Tripartite Complex Activator To Treat Wilson Disease The FDA has authorized Monopar to submit the NDA on a rolling basis, allowing completed sections of the application to be submitted and reviewed while the Company finalizes the remaining sections.…
benzinga.com Monopar Says FDA Grants Rare Pediatric Disease Designation To ALXN1840, Late-Stage Candidate For Treatment Of Wilson Disease Monopar Therapeutics Inc. ("Monopar" or the "Company") (NASDAQ:MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced- benzinga.com BTIG Maintains Buy on Monopar Therapeutics, Raises Price Target to $117 BTIG analyst Jeet Mukherjee maintains Monopar Therapeutics (NASDAQ:MNPR) with a Buy and raises the price target from $104 to $117.
- benzinga.com HC Wainwright & Co. Reiterates Buy on Monopar Therapeutics, Maintains $105 Price Target HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Monopar Therapeutics (NASDAQ:MNPR) with a Buy and maintains $105 price target.
benzinga.com Monopar Therapeutics To Present New Analyses From Phase 3 FoCus Randomized Clinical Trial Of ALXN1840 At EAN 2026. Key findings presented at EAN 2026:In the subset of patients with neurologic symptoms at baseline from the 2:1 randomized Phase 3 FoCus clinical trial (NCT03403205; n=207), ALXN1840 demonstrated…
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session Gainers Aditxt (NASDAQ:ADTX) shares increased by 151.6% to $0.05 during Tuesday's regular session. Atlantic International (NASDAQ:ATLN) stock rose 143.31% to $1.07. The market value of their…
benzinga.com Monopar Therapeutics Publishes Phase 2 Study Demonstrating ALXN1840 Improves Copper Balance In Patients With Wilson Disease Monopar Therapeutics Inc. ("Monopar" or the "Company") (NASDAQ:MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced- benzinga.com Monopar Therapeutics Q4 EPS $(0.61) Misses $(0.54) Estimate Monopar Therapeutics (NASDAQ:MNPR) reported quarterly losses of $(0.61) per share which missed the analyst consensus estimate of $(0.54) by 12.96 percent. This is a 72.65 percent increase over losses…
- benzinga.com BTIG Reiterates Buy on Monopar Therapeutics, Maintains $104 Price Target BTIG analyst Jeet Mukherjee reiterates Monopar Therapeutics (NASDAQ:MNPR) with a Buy and maintains $104 price target.
- benzinga.com BTIG Reiterates Buy on Monopar Therapeutics, Maintains $104 Price Target BTIG analyst Jeet Mukherjee reiterates Monopar Therapeutics (NASDAQ:MNPR) with a Buy and maintains $104 price target.
benzinga.com BTIG Reiterates Buy on Monopar Therapeutics, Maintains $104 Price Target BTIG analyst Jeet Mukherjee reiterates Monopar Therapeutics (NASDAQ:MNPR) with a Buy and maintains $104 price target.- benzinga.com Morgan Stanley Initiates Coverage On Monopar Therapeutics with Overweight Rating, Announces Price Target of $115 Morgan Stanley analyst Maxwell Skor initiates coverage on Monopar Therapeutics (NASDAQ:MNPR) with a Overweight rating and announces Price Target of $115.
benzinga.com The Year-End 2025 Biotech Rally And What It Means For 2026 
benzinga.com This Home Depot Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday - benzinga.com Raymond James Downgrades Monopar Therapeutics to Outperform, Lowers Price Target to $123 Raymond James analyst Chris Raymond downgrades Monopar Therapeutics (NASDAQ:MNPR) from Strong Buy to Outperform and lowers the price target from $142 to $123.
- benzinga.com Chardan Capital Maintains Buy on Monopar Therapeutics, Maintains $100 Price Target Chardan Capital analyst Keay Nakae maintains Monopar Therapeutics (NASDAQ:MNPR) with a Buy and maintains $100 price target.
- benzinga.com Monopar Therapeutics Q3 EPS $(0.48) Misses $(0.45) Estimate Monopar Therapeutics (NASDAQ:MNPR) reported quarterly losses of $(0.48) per share which missed the analyst consensus estimate of $(0.45) by 7.38 percent. This is a 29.73 percent decrease over losses…
- benzinga.com Chardan Capital Maintains Buy on Monopar Therapeutics, Raises Price Target to $100 Chardan Capital analyst Keay Nakae maintains Monopar Therapeutics (NASDAQ:MNPR) with a Buy and raises the price target from $85 to $100.
- benzinga.com Leerink Partners Initiates Coverage On Monopar Therapeutics with Outperform Rating, Announces Price Target of $115 Leerink Partners analyst Joseph Schwartz initiates coverage on Monopar Therapeutics (NASDAQ:MNPR) with a Outperform rating and announces Price Target of $115.
benzinga.com This Monopar Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday 
benzinga.com This Hilton Worldwide Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session
benzinga.com Why Deckers Outdoor Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket - benzinga.com Why Peraso Shares Are Trading Lower By Over 23%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session Shares of Peraso Inc. (NASDAQ: PRSO) fell sharply during Tuesday’s session after the company reported worse-than-expected fourth-quarter EPS results.
- benzinga.com Why Fluor Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session Shares of Fluor Corporation (NYSE: FLR) fell during Tuesday’s session following fourth-quarter results.
- benzinga.com Stocks That Hit 52-Week Lows On Thursday On Thursday, 128 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Thursday On Thursday, 109 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Thursday Thursday's session saw 189 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Friday Friday's session saw 104 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Tuesday Tuesday's session saw 286 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Tuesday On Tuesday, 91 stocks hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Wednesday On Wednesday, 220 stocks hit new 52-week lows.
- benzinga.com Benzinga's Top Ratings Upgrades, Downgrades For March 29, 2023
- benzinga.com Stocks That Hit 52-Week Lows On Tuesday During Tuesday, 95 stocks hit new 52-week lows.
- benzinga.com Why Alibaba Shares Are Trading Higher By Over 8%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session Gainers
- benzinga.com Why Apyx Medical Shares Dipped Over 60%; Here Are 123 Biggest Movers From Yesterday Gainers
- benzinga.com Stocks That Hit 52-Week Lows On Friday During Friday's session, 574 stocks hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Friday On Friday, 1043 companies hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Thursday During Thursday, 351 stocks hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Thursday During Thursday, 849 stocks hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Monday On Monday, 721 companies achieved new lows for the year.